Layered slow-release phosphatidylserine and sleep aid factor nutritional formula and preparation process

Abstract

The present application relates to the technical field of functional food preparation, and discloses a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula and a preparation process, the formula comprising the following components by weight: phosphatidylserine: 0.5-1.7 parts; caprylic / capric triglyceride: 1.5-8.5 parts; sodium octenyl succinate starch: 0.8-3.5 parts; whey protein isolate: 0.4-2.0 parts; soy lecithin: 0.008-0.05 parts; mixed tocopherols: 0.0005-0.005 parts; ascorbic acid palmitate: 0.0002-0.003 parts; gamma-aminobutyric acid: 0.3-0.8 parts; L-theanine: 0.5-1.0 parts; glycine: 6.0-15.0 parts; magnesium glycinate: 2.0-5.5 parts. The present application realizes high stability and intestinal sustained release of PS microcapsule emulsion and stomach rapid release of sleep-aiding factors through microfluidic multilayer wet integration technology.

Description

Technical Field

[0001] This invention relates to the field of functional food or nutritional health product preparation technology, specifically to a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula and preparation process. Background Technology

[0002] Phosphatidylserine (PS) is an important bioactive lipid component, often used to improve cognition and relieve stress. Meanwhile, water-soluble factors such as gamma-aminobutyric acid (GABA) and L-theanine are also recognized sleep-aiding nutrients. The scientific combination of fat-soluble phosphatidylserine with water-soluble sleep-aiding factors to achieve synergistic effects is a current trend in nutritional health product development.

[0003] In existing technologies, microencapsulation is commonly used to protect lipid-soluble active ingredients like PS. For example, PS is dissolved in oils and then mixed with an aqueous wall material. This mixture is then emulsified under high shear or high pressure, and finally spray-dried to prepare microcapsule powder. For compound products, a common practice is to mix all functional components, such as PS, GABA, and L-theanine, with the wall material additives in a liquid phase, followed by integrated encapsulation and drying; alternatively, the prepared PS microcapsule powder can be simply physically mixed with other powdered raw materials such as GABA and L-theanine.

[0004] Although existing technologies offer some preparation ideas, there are still some shortcomings: First, the molecular structure of phosphatidylserine makes it very sensitive to oxygen and heat. During conventional hot air drying, mixing, packaging and other processes, prolonged exposure to air (oxygen) and high temperatures can easily lead to oxidative degradation, resulting in poor product stability.

[0005] Secondly, existing compounding processes struggle to achieve synergistic and temporal regulation of the functions of multiple components. By employing simple physical mixing methods, all water-soluble sleep-aiding factors are released almost simultaneously and rapidly with PS after ingestion, resulting in a short physiological duration and an inability to create a long-lasting, sustained sleep-aiding effect.

[0006] Finally, using traditional integrated encapsulation technology, the random mixing of water-soluble factors such as GABA and L-theanine with PS in the emulsion leads to a chaotic encapsulation structure, making it impossible to distinguish between the core layer and the coating layer. This makes the release behavior of all components uncontrollable, failing to achieve effective sustained release of PS or the layer-by-layer or continuous release of sleep-aiding factors, and making it difficult to construct a stable and continuous physiological effect curve. Furthermore, the capsule wall structure formed by conventional high-shear or homogenization processes is usually not dense enough, resulting in a low encapsulation rate, which also leads to poor sustained-release effects of PS. Summary of the Invention

[0007] To address the shortcomings of existing technologies, this invention provides a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula and preparation process, which solves the problems of easy oxidation of active lipids (phosphatidylserine) and incompatibility with the physicochemical properties of water-soluble functional factors (sleep-aiding factors) and conflict with release kinetic requirements.

[0008] To achieve the above objectives, the present invention provides the following technical solution: In a first aspect, the present invention provides a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, employing the following technical solution: A layered, sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, comprising the following components by weight: Phosphatidylserine: 0.5-1.7 parts; Caprylic / capric triglycerides: 1.5-8.5 parts; Sodium octenyl succinate starch: 0.8-3.5 parts; Whey protein isolate: 0.4-2.0 parts; Soy lecithin: 0.008-0.05 parts; Mixed tocopherols: 0.0005-0.005 parts; Palmitic acid ascorbate: 0.0002-0.003 parts; γ-Aminobutyric acid: 0.3-0.8 parts; L-Theanine: 0.5-1.0 parts; Glycine: 6.0-15.0 parts; Magnesium glycine: 2.0-5.5 parts.

[0009] By adopting the above technical solution, and by using a specific lipid complex system and amino acid combination, the following effects are achieved: Lipid carrier stabilization: Caprylic / capric triglyceride (MCT) serves as the carrier oil, promoting the dissolution and dispersion of phosphatidylserine. It also adjusts the density of the oil phase to match the interfacial tension with the aqueous phase wall material. Combined with a compound antioxidant consisting of mixed tocopherols and palmitic acid ascorbate, an antioxidant barrier is constructed inside the microcapsule core, blocking the initiation of the lipid peroxidation chain reaction.

[0010] Multidimensional sleep aid synergy: The high content of glycine and glycine magnesium in the formula provides the basic substrate for neurotransmitter regulation, working synergistically with γ-aminobutyric acid (GABA) and L-theanine to play a role in relieving nervous tension and regulating brain waves.

[0011] Wall material network construction: The composite wall material system formed by sodium octenyl succinate starch, whey protein isolate, and soybean lecithin utilizes the electrostatic interaction and amphiphilic properties of proteins and polysaccharides to provide a material basis for the formation of dense capsule walls during the subsequent microencapsulation process.

[0012] Preferably, the nutritional formula further includes at least one selected from microcrystalline cellulose and maltodextrin; the amount of microcrystalline cellulose added is 1.0-2.0 parts; the amount of maltodextrin added is 0.3-1.0 parts; and the content of elemental magnesium in the glycine magnesium is 0.3-0.8 parts.

[0013] By adopting the above technical solution, microcrystalline cellulose and maltodextrin are used as fillers and excipients to improve the flowability and compressibility of the final powder, which helps the product maintain physical stability during long-term storage and prevents clumping.

[0014] Secondly, the present invention provides a preparation process for a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, which adopts the following technical solution: A preparation process for a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula includes the following steps: S1. Construct a phosphatidylserine oil phase containing an antioxidant system; S2. Preparation of aqueous emulsion for composite wall material; S3. Prepare a water-soluble sleep-aiding compound factor solution; S4. Microencapsulate and compact the phosphatidylserine oil phase and the composite wall material aqueous phase emulsion to form a PS microencapsulated emulsion. Then, inject the water-soluble sleep aid composite factor solution for encapsulation and compact and encapsulate it with the wall material again to obtain a multilayer microencapsulated composite emulsion. S5. Spray dry the multilayer microencapsulated composite emulsion to obtain multilayer microencapsulated composite powder. S6. The multilayer microencapsulated composite powder is packaged with high-barrier nitrogen filling.

[0015] By adopting the above technical solution, this invention achieves the protection and graded release of active ingredients through stepwise regulation and microstructure recombination, and the mechanism is as follows: Oil phase deoxygenation and pre-stabilization (for step S1): The process involves dissolving phosphatidylserine in MCT at 40-55℃ and bubbling with nitrogen gas to displace dissolved oxygen in the system using the gas-liquid mass transfer principle. This process controls the peroxide value of the oil phase below 0.5 mmol / kg, reducing endogenous factors that may trigger oxidation during thermal processing and helping to ensure the initial activity of the core active ingredients.

[0016] Interface enhancement and multilayer integration (for steps S2, S3 and S4): First, in step S2, sodium octenyl succinate starch and whey protein isolate are arranged in an orderly manner in the aqueous phase through high shear and homogenization treatment to form an interface film precursor.

[0017] Subsequently, in step S4, the fluid focusing technology of the microfluidic chip is used to bring the oil and water phases into contact in a laminar flow state, forming PS droplets with uniform particle size. Then, as these droplets flow through the swirling microstructure downstream of the chip, the tangential shear force generated by the fluid dynamics drives the droplet surface to swirl. This physical-mechanical force causes the protein and polysaccharide molecular chains at the interface to rearrange and compact, compressing the loose emulsion interface into a dense inner capsule wall.

[0018] The microfluidic chip system utilizes fluid focusing technology to achieve controlled encapsulation of oil and aqueous phases. Phosphatidylserine in the oil phase and sleep-aiding factors in the aqueous phase are separately formulated and precisely proportioned under flow conditions to form microcapsules with well-defined inner and outer layer structures. As droplets flow through the swirling microstructure, the tangential stress of the fluid causes the wall material to densify, thereby forming a PS microcapsule core with a high encapsulation rate, ensuring effective protection of the inner layer components.

[0019] Next, a water-soluble sleep-aiding complex solution prepared by S3 was injected into the downstream channel of the chip, coating the PS microcapsules. After further compaction and wall material coating, a multi-layered microencapsulated complex with a clear interface was constructed from the inside out. The sleep-aiding factors in the aqueous phase formed an ordered coating layer through a composite wall material composed of sodium octenyl succinate starch, whey protein, and soybean lecithin. During the molding process, the cross-linking and self-assembly of the wall material promoted interface stability, thereby preventing rapid release of nutrients into the stomach. Furthermore, the synergistic effect of the hydrophilic and hydrophobic properties of the wall material balanced the release rates of the two layers.

[0020] This dense, multi-layered structure reduces the permeability of oxygen and water, achieving physical isolation and protection for the internal phosphatidylserine, thereby effectively prolonging its activity and stability and preventing oxidation and hydrolysis reactions. Specifically, the outer layer components (such as water-soluble sleep-aiding factors γ-aminobutyric acid and L-theanine) can be released rapidly to meet the need for quick sleep; while the inner layer components (such as phosphatidylserine) are released slowly through the intestines to support nerve repair and deep sleep.

[0021] Non-destructive drying and structural curing (for step S5): Nitrogen circulating spray drying is used to instantly dehydrate the multilayer microencapsulated composite emulsion in a low-oxygen (1-5% v / v) environment. Since the wall material has been densified and formed a multilayer structure in step S4, the capsule walls are not prone to collapse or breakage during the drying process, thereby obtaining a high encapsulation rate (85-99%), single-particle multilayer microencapsulated composite powder.

[0022] Multilayer structure and layer-by-layer release (for steps S4 and S5): This process employs wet integration. The water-soluble sleep-aiding factor solution prepared in step S3 is precisely coated onto the exterior of the PS microcapsules in step S4, forming independent wall layers. Drying in step S5 solidifies this multilayer structure. This design microscopically constructs multilayer release units within a single particle: Outer release unit: Water-soluble sleep-aiding factors such as GABA, theanine, and glycine are located on the outer layer of the particles. They can dissolve first after entering the human body and are used to quickly induce sleep. Inner sustained-release unit: The dense PS microcapsule core is located in the inner layer of the particle. After the external sleep aid factor is released, the inner capsule wall begins to gradually disintegrate in the intestinal environment, releasing phosphatidylserine to maintain nerve repair and deep sleep quality during sleep.

[0023] Terminal activity lock-in (for step S6): The final high-barrier nitrogen-filled packaging controls the headspace oxygen content in the packaging to 1-5%. Combined with the dense wall material of the microcapsules, it forms a triple protection system consisting of packaging, wall material and antioxidant, which helps stabilize the product's potency during its shelf life.

[0024] Preferably, S1 includes the following steps: mixing phosphatidylserine with caprylic / capric triglycerides, adding mixed tocopherols and palmitic ascorbate, stirring to dissolve under constant temperature of 40-55°C, and bubbling with nitrogen gas for 5-10 minutes to remove dissolved oxygen, thereby obtaining a phosphatidylserine oil phase with a peroxide value in the range of 0.1-0.5 mmol / kg.

[0025] By employing the above technical solution, the mixture of phosphatidylserine and caprylic / capric triglycerides provides a suitable fluid viscosity, which helps ensure the flow stability within the microfluidic channel and prevents the risk of demulsification due to excessive oil phase content. Combined with strict deoxygenation parameters, this solution yields an oil phase that meets process requirements.

[0026] Preferably, step S2 includes the following steps: dissolving sodium octenyl succinate starch, whey protein isolate and soybean lecithin in water, pre-emulsifying them for 3-8 minutes at 8000-15000 rpm using a high-shear emulsifier, and then subjecting them to two-stage high-pressure homogenization or membrane emulsification to form a composite wall material aqueous emulsion with a particle size distribution coefficient (SPAN) in the range of 0.8-1.0.

[0027] By adopting the above technical solution, the particle size distribution coefficient (SPAN≤1.0) is strictly controlled to ensure the uniformity of the aqueous emulsion. This helps to form microcapsules of uniform size and wall thickness during the microfluidic process, avoiding encapsulation defects caused by particle size differences.

[0028] Preferably, step S4 includes the following steps: pumping the phosphatidylserine oil phase obtained in step S1 and the composite wall material aqueous emulsion obtained in step S2 into a microfluidic chip system, so that the oil phase and aqueous phase form embedded droplets in the fluid focusing channel; in the microfluidic chip, the oil phase and aqueous phase are introduced by independent channels and are in a typical laminar flow state in the microscale channel. At the fluid focusing node, the oil phase is radially compressed and stretched by the high-speed flowing aqueous phase on both sides to form a slender liquid column. As the local interfacial tension and shear stress reach the instability condition, the oil phase liquid column undergoes periodic necking fracture at a specific position, generating oil phase droplets with uniform particle size and height.

[0029] At the moment of droplet formation, sodium octenyl succinate starch, whey protein isolate, and soybean lecithin in the aqueous phase rapidly migrate to the oil-water interface and are directionally adsorbed under the drive of interfacial tension. Their hydrophobic groups are embedded in the oil phase, while their hydrophilic groups face the outer aqueous phase, spontaneously constructing a continuous and dense interfacial film layer, so that the oil phase is stably coated in the core position, forming a primary embedded droplet with a clear oil core-water shell structure.

[0030] This process achieves natural stratification of the inner and outer phases through the controllable interfacial instability and interfacial energy minimization mechanism generated by fluid focusing. Structurally, it ensures that the phosphatidylserine oil phase is stably confined in the microcapsule core, providing a stable structural basis for the subsequent introduction of water-soluble sleep-aiding factors in the downstream flow channel and the construction of the outer coating.

[0031] The primary embedded droplet flows through the swirling microstructure downstream of the chip and generates swirling motion under the action of fluid tangential stress, which compacts the surface wall material and forms PS microcapsule emulsion. Subsequently, the water-soluble sleep-aiding composite factor solution prepared in step S3 is injected into the downstream channel of the microfluidic chip, so that it coats the surface of the PS microcapsule emulsion and flows through the subsequent swirling microstructure and wall material coating channel to form a multilayer microencapsulated composite emulsion.

[0032] By adopting the above technical solution, the integration path of multiple components in the liquid phase was clarified. The core-shell structure was formed by fluid focusing, and the wall material density was enhanced by the mechanical action of the swirling microstructure, thereby constructing a multilayer microcapsule structure with layer-by-layer release characteristics.

[0033] Preferably, step S5 includes the following steps: feeding the multilayer microencapsulated composite emulsion obtained in step S4 into a nitrogen circulating spray drying tower, controlling the inlet temperature to be 160-185℃, the outlet temperature to be 75-85℃, the drying medium to be nitrogen and the outlet oxygen content to be 1-5% v / v, to obtain multilayer microencapsulated composite powder with an encapsulation rate of 85-99%.

[0034] By adopting the above technical solution, low oxygen and a specific inlet and outlet temperature gradient balance drying efficiency and protection of heat-sensitive components, which helps to preserve the integrity of the multilayer microcapsule structure.

[0035] Preferably, step S3 includes the following steps: dissolving γ-aminobutyric acid, L-theanine, glycine, and magnesium glycine in purified water at an ambient temperature of 15-24°C and a relative humidity of 20-39%; optionally, adding maltodextrin or microcrystalline cellulose to adjust the solution viscosity to obtain a water-soluble sleep-aiding compound factor solution.

[0036] By adopting the above technical solution, the water-soluble factor is pre-prepared into a solution, which is a prerequisite for subsequent liquid phase coating in the microfluidic chip and helps to ensure the uniformity of the outer coating.

[0037] Preferably, step S6 includes the following steps: using aluminum foil composite high-barrier packaging material to package the multi-layer microencapsulated compound powder obtained in step S5, and performing nitrogen purging before heat sealing to control the headspace oxygen content in the packaging to 1-5%, thereby obtaining a high-barrier nitrogen-filled packaging product.

[0038] By adopting the above technical solution, the final protection during the commercial distribution of the product is provided, ensuring that the product is in a low-oxygen protection state until it is opened by the consumer.

[0039] This invention provides a stratified, sustained-release phosphatidylserine and sleep-aiding factor nutritional formula and preparation process. It has the following beneficial effects: 1. This invention constructs a triple low-oxygen protection barrier from raw materials to finished products by adding a composite antioxidant system of mixed tocopherol and palmitic acid ascorbate to the oil phase of phosphatidylserine, and combining it with a series of measures such as nitrogen bubbling deoxygenation, nitrogen circulating spray drying, full-process low-oxygen environment control, and high-barrier nitrogen-filled packaging. This fundamentally inhibits the oxidation of phosphatidylserine during processing and storage, significantly improving the long-term oxidative stability of the product.

[0040] 2. This invention employs microfluidic chip technology to encapsulate the phosphatidylserine oil phase and utilizes downstream swirling microstructures to generate tangential stress that compacts the wall material, forming a dense, highly encapsulated PS microcapsule core layer. This structure provides a strong physical barrier for phosphatidylserine, forming the structural basis for its efficient protection and subsequent sustained-release.

[0041] 3. This invention utilizes a multi-level integration process with microfluidic chips to precisely inject and encapsulate a water-soluble sleep-aiding factor solution into the liquid flow channel after the PS microcapsule emulsion is formed. This is followed by a second swirl compaction, ultimately producing a single-particle, multi-layered microencapsulated complex with a clear interface. This precise structural design overcomes the shortcomings of traditional integrated encapsulation methods, enabling the layered and continuous release of various functional factors in vivo. Specifically, the outer layer of water-soluble sleep-aiding factors is rapidly released to induce sleep, while the inner PS core releases slowly to maintain deep sleep, thus constructing a stable and continuous physiological effect curve. Attached Figure Description

[0042] Figure 1 This is a schematic diagram of the microencapsulation compounding and integration process of the present invention; Figure 2 for Figure 1 Enlarged view of point A in the middle; Figure 3 This is a schematic diagram of the wall material rolling and pressing process of the present invention.

[0043] Among them, 1. Aqueous phase injection port; 2. Composite wall material aqueous phase emulsion; 3. Oil phase injection port; 4. Phosphatidylserine oil phase; 5. Swirled microstructure; 6. Water-soluble sleep aid composite factor; 7. Multilayer microencapsulated composite complex. Detailed Implementation

[0044] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0045] Please refer to the appendix. Figure 1 -Appendix Figure 3 : The main raw materials and reagents used in the following examples and comparative examples have the following sources and specifications. Reagents not specifically mentioned are all commercially available analytical grade or higher grade products.

[0046] Phosphatidylserine (CAS No.: 51446-62-9), food grade, purity ≥50%; Caprylic / capric triglyceride (CAS No.: 65381-09-1), food grade; Sodium octenyl succinate starch (CAS No.: 66829-29-6), food grade; Whey protein isolate, food grade, protein content ≥90%; Soy lecithin (CAS No.: 8002-43-5), food grade; Palmitic ascorbate (CAS No.: 137-66-6), food grade; γ-Aminobutyric acid (CAS No.: 56-12-2), food grade, purity ≥98%; L-Theanine (CAS No.: 3081-61-6), food grade, purity ≥98%; Glycine (CAS No.: 56-40-6), food grade; Magnesium glycine (CAS No.: 14783-68-7), food grade; Microcrystalline cellulose (CAS No.: 9004-34-6), food grade; Maltodextrin (CAS No.: 9050-36-6), food grade.

[0047] Preparation Example 1: This preparation example provides a method for preparing mixed tocopherols, including the following steps: Add 20 parts by weight of α-tocopherol (CAS No.: 10191-41-0), 50 parts by weight of γ-tocopherol (CAS No.: 54-28-4), and 30 parts by weight of δ-tocopherol (CAS No.: 119-13-1) to the reaction flask.

[0048] With stirring at 120 rpm, a nitrogen stream was introduced into the headspace of the reaction flask at a flow rate of 0.1 L / min for 5 minutes to replace the air in the container.

[0049] Under nitrogen protection and at 22°C, the mixture was stirred at low speed for 18 minutes to obtain a mixed tocopherol.

[0050] Example 1: This embodiment provides a layered slow-release phosphatidylserine and sleep-aiding factor nutritional formula, comprising the following components by weight: phosphatidylserine: 1.7 parts; caprylic / capric triglycerides: 8.5 parts; sodium octenyl succinate starch: 3.5 parts; whey protein isolate: 2.0 parts; soybean lecithin: 0.05 parts; mixed tocopherols: 0.005 parts; palmitic ascorbate: 0.003 parts; γ-aminobutyric acid: 0.8 parts; L-theanine: 1.0 part; glycine: 15.0 parts; magnesium glycine: 5.5 parts; microcrystalline cellulose: 2.0 parts.

[0051] This embodiment also provides a preparation process for a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, including the following steps: S1. Constructing a phosphatidylserine oil phase containing an antioxidant system: 1.7 parts of phosphatidylserine and 8.5 parts of caprylic / capric triglycerides were mixed, and 0.005 parts of mixed tocopherols and 0.003 parts of palmitic ascorbate were added. The mixture was stirred and dissolved at a constant temperature of 55°C, and nitrogen gas was bubbled through for 10 minutes to remove dissolved oxygen, thus obtaining a phosphatidylserine oil phase with a peroxide value of 0.1 mmol / kg. S2. Preparation of composite wall material aqueous emulsion: Dissolve 3.5 parts of sodium octenyl succinate starch, 2.0 parts of whey protein isolate and 0.05 parts of soybean lecithin in water, and pre-emulsify for 8 minutes at 15,000 rpm using a high-shear emulsifier. Then, perform two-stage high-pressure homogenization to form a composite wall material aqueous emulsion with a particle size distribution coefficient (SPAN) in the range of 0.8. S3. Preparation of water-soluble sleep-aiding compound factor solution: Dissolve 0.8 parts of γ-aminobutyric acid, 1.0 parts of L-theanine, 15.0 parts of glycine, 5.5 parts of magnesium glycine and 2.0 parts of microcrystalline cellulose in purified water at an ambient temperature of 24℃ and a relative humidity of 39%, and stir for 10 minutes to obtain a water-soluble sleep-aiding compound factor solution. S4. Microencapsulation and Multilayer Wet Integration: The phosphatidylserine oil phase prepared in step S1 and the composite wall material aqueous emulsion prepared in step S2 are pumped into the microfluidic chip system. The oil phase and aqueous phase form encapsulated droplets in the fluid focusing channel. The encapsulated droplets flow through the swirling microstructure downstream of the chip and generate swirling motion under the action of fluid tangential stress, which compacts the surface wall material to form a PS microencapsulated emulsion. Subsequently, the water-soluble sleep-aiding composite factor solution prepared in step S3 is injected into the downstream channel of the microfluidic chip to coat the surface of the PS microencapsulated emulsion and flow through the subsequent swirling microstructure and wall material coating channel to form a multilayer microencapsulated composite emulsion. S5. Spray drying of the multilayer microencapsulated composite emulsion: The multilayer microencapsulated composite emulsion obtained in step S4 is fed into a nitrogen circulating spray drying tower, with the inlet temperature controlled at 185℃ and the outlet temperature at 85℃. The drying medium is nitrogen and the oxygen content of the outlet air is 5% v / v, to obtain multilayer microencapsulated composite powder with an encapsulation rate of 99%. S6. High-barrier nitrogen-filled packaging of multi-layer microencapsulated composite powder: Multi-layer microencapsulated composite powder is packaged using aluminum foil composite high-barrier packaging material, and nitrogen is replaced before heat sealing to control the headspace oxygen content in the packaging to 5%, thus obtaining a high-barrier nitrogen-filled packaged product.

[0052] Example 2: This embodiment provides a layered slow-release phosphatidylserine and sleep-aiding factor nutritional formula, comprising the following components by weight: phosphatidylserine: 0.5 parts; caprylic / capric triglycerides: 1.5 parts; sodium octenyl succinate starch: 0.8 parts; whey protein isolate: 0.4 parts; soybean lecithin: 0.008 parts; mixed tocopherols: 0.0005 parts; palmitic ascorbate: 0.0002 parts; γ-aminobutyric acid: 0.3 parts; L-theanine: 0.5 parts; glycine: 6.0 parts; magnesium glycine: 2.0 parts; maltodextrin: 0.3 parts.

[0053] This embodiment also provides a preparation process for a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, including the following steps: S1. Constructing a phosphatidylserine oil phase containing an antioxidant system: Mix 0.5 parts of phosphatidylserine with 1.5 parts of caprylic / capric triglycerides, add 0.0005 parts of mixed tocopherols and 0.0002 parts of palmitic ascorbate, stir and dissolve at a constant temperature of 40°C, and bubble with nitrogen for 5 minutes to remove dissolved oxygen, to obtain a phosphatidylserine oil phase with a peroxide value of 0.5 mmol / kg; S2. Preparation of composite wall material aqueous emulsion: Dissolve 0.8 parts of sodium octenyl succinate starch, 0.4 parts of whey protein isolate and 0.008 parts of soybean lecithin in water, and pre-emulsify for 3 minutes at 8000 rpm using a high-shear emulsifier, followed by membrane emulsification treatment to form a composite wall material aqueous emulsion with a particle size distribution coefficient (SPAN) in the range of 1.0. S3. Preparation of water-soluble sleep-aiding compound factor solution: Dissolve 0.3 parts γ-aminobutyric acid, 0.5 parts L-theanine, 6.0 parts glycine, 2.0 parts magnesium glycine and 0.3 parts maltodextrin in purified water at an ambient temperature of 15℃ and a relative humidity of 20%, and stir for 5 minutes to obtain a water-soluble sleep-aiding compound factor solution. S4. Microencapsulation and multilayer wet integration: The process is the same as step S4 in Example 1; S5. Spray drying of the multilayer microencapsulated composite emulsion: The multilayer microencapsulated composite emulsion obtained in step S4 is fed into a nitrogen circulating spray drying tower, with the inlet temperature controlled at 160℃ and the outlet temperature at 75℃. The drying medium is nitrogen and the oxygen content of the outlet air is 1%v / v, to obtain multilayer microencapsulated composite powder with an encapsulation rate of 85%. S6. High-barrier nitrogen-filled packaging of multi-layer microencapsulated composite powder: Multi-layer microencapsulated composite powder is packaged using aluminum foil composite high-barrier packaging material, and nitrogen is replaced before heat sealing to control the headspace oxygen content in the packaging to 1%, thus obtaining a high-barrier nitrogen-filled packaging product.

[0054] Example 3: This embodiment provides a layered slow-release phosphatidylserine and sleep-aiding factor nutritional formula, comprising the following components by weight: phosphatidylserine: 1.0 part; caprylic / capric triglyceride: 4.0 part; sodium octenyl succinate starch: 2.0 part; whey protein isolate: 1.0 part; soybean lecithin: 0.02 part; mixed tocopherols: 0.002 part; palmitic ascorbate: 0.001 part; γ-aminobutyric acid: 0.5 part; L-theanine: 0.7 part; glycine: 10.0 part; magnesium glycine: 3.5 part.

[0055] This embodiment also provides a preparation process for a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, including the following steps: S1. Constructing a phosphatidylserine oil phase containing an antioxidant system: 1.0 part of phosphatidylserine and 4.0 parts of caprylic / capric triglycerides were mixed, and 0.002 parts of mixed tocopherols and 0.001 parts of palmitic ascorbate were added. The mixture was stirred and dissolved at a constant temperature of 45°C, and nitrogen gas was bubbled through for 8 minutes to remove dissolved oxygen, thus obtaining a phosphatidylserine oil phase with a peroxide value of 0.3 mmol / kg. S2. Preparation of composite wall material aqueous emulsion: 2.0 parts of sodium octenyl succinate starch, 1.0 parts of whey protein isolate and 0.02 parts of soybean lecithin were dissolved in water and pre-emulsified at 12,000 rpm for 5 minutes using a high-shear emulsifier. Then, the emulsion was subjected to two-stage high-pressure homogenization to form a composite wall material aqueous emulsion with a particle size distribution coefficient (SPAN) in the range of 0.9. S3. Preparation of water-soluble sleep-aiding compound factor solution: Dissolve 0.5 parts of γ-aminobutyric acid, 0.7 parts of L-theanine, 10.0 parts of glycine and 3.5 parts of magnesium glycine in purified water at an ambient temperature of 20℃ and a relative humidity of 30%, and stir for 8 minutes to obtain a water-soluble sleep-aiding compound factor solution. S4. Microencapsulation and multilayer wet integration: The process is the same as step S4 in Example 1; S5. Spray drying of the multilayer microencapsulated composite emulsion: The multilayer microencapsulated composite emulsion obtained in step S4 is fed into a nitrogen circulating spray drying tower, with the inlet temperature controlled at 170℃ and the outlet temperature at 80℃. The drying medium is nitrogen and the oxygen content of the outlet air is 3%v / v, to obtain multilayer microencapsulated composite powder with an encapsulation rate of 95%. S6. High-barrier nitrogen-filled packaging of multi-layer microencapsulated composite powder: Multi-layer microencapsulated composite powder is packaged using aluminum foil composite high-barrier packaging material, and nitrogen is replaced before heat sealing to control the headspace oxygen content in the packaging to 3%, thus obtaining a high-barrier nitrogen-filled packaging product.

[0056] Example 4: This embodiment provides a layered slow-release phosphatidylserine and sleep-aiding factor nutritional formula, comprising the following components by weight: phosphatidylserine: 1.2 parts; caprylic / capric triglycerides: 4.8 parts; sodium octenyl succinate starch: 2.5 parts; whey protein isolate: 1.5 parts; soybean lecithin: 0.03 parts; mixed tocopherols: 0.003 parts; palmitic ascorbate: 0.0015 parts; γ-aminobutyric acid: 0.6 parts; L-theanine: 0.8 parts; glycine: 12.0 parts; magnesium glycine: 4.0 parts; microcrystalline cellulose: 1.5 parts.

[0057] This embodiment also provides a preparation process for a layered slow-release phosphatidylserine and sleep-aiding factor nutritional formula, the process parameters of which are basically the same as those in Embodiment 3.

[0058] S1: The oil phase formulation is added according to the components of this embodiment, and the process parameters (45℃, 8 minutes) are the same as in Example 3; S2: The aqueous phase formulation is added according to the components of this embodiment, and the process parameters (12000 rpm, 5 minutes) are the same as in embodiment 3; S3. Preparation of water-soluble sleep-aiding compound factor solution: The sleep-aiding module formula is added according to the components of this embodiment (containing 1.5 parts microcrystalline cellulose), and dissolved in purified water under the conditions of ambient temperature of 20℃ and relative humidity of 30%. The mixture is stirred and mixed for 8 minutes to obtain a water-soluble sleep-aiding compound factor solution. S4. Microencapsulation and multilayer wet integration: The process is the same as step S4 in Example 1; S5. Spray drying of the multilayer microencapsulated complex emulsion: process parameters (inlet 170℃, outlet 80℃, O2 3%) are the same as in Example 3, to obtain multilayer microencapsulated complex powder with an encapsulation rate of 94%. S6. High-barrier nitrogen-filled packaging of multilayer microencapsulated compound powder: process parameters (headspace O2 3%) are the same as in Example 3.

[0059] Example 5: This embodiment provides a layered slow-release phosphatidylserine and sleep-aiding factor nutritional formula, comprising the following components by weight: phosphatidylserine: 0.8 parts; caprylic / capric triglycerides: 3.2 parts; sodium octenyl succinate starch: 1.5 parts; whey protein isolate: 0.8 parts; soybean lecithin: 0.01 parts; mixed tocopherols: 0.001 parts; palmitic ascorbate: 0.0005 parts; γ-aminobutyric acid: 0.4 parts; L-theanine: 0.6 parts; glycine: 8.0 parts; magnesium glycine: 3.0 parts; maltodextrin: 0.8 parts.

[0060] This embodiment also provides a preparation process for a layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula, including the following steps: S1. Constructing a phosphatidylserine oil phase containing an antioxidant system: Mix 0.8 parts of phosphatidylserine with 3.2 parts of caprylic / capric triglycerides, add 0.001 parts of mixed tocopherols and 0.0005 parts of palmitic ascorbate, stir and dissolve at a constant temperature of 50°C, and bubble with nitrogen for 7 minutes to remove dissolved oxygen, to obtain a phosphatidylserine oil phase with a peroxide value of 0.2 mmol / kg; S2. Preparation of composite wall material aqueous emulsion: 1.5 parts of sodium octenyl succinate starch, 0.8 parts of whey protein isolate and 0.01 parts of soybean lecithin were dissolved in water and pre-emulsified for 6 minutes at 10,000 rpm using a high-shear emulsifier. Then, the mixture was subjected to two-stage high-pressure homogenization to form a composite wall material aqueous emulsion with a particle size distribution coefficient (SPAN) in the range of 0.95. S3. Preparation of water-soluble sleep-aiding compound factor solution: Dissolve 0.4 parts of γ-aminobutyric acid, 0.6 parts of L-theanine, 8.0 parts of glycine, 3.0 parts of magnesium glycine and 0.8 parts of maltodextrin in purified water at an ambient temperature of 22℃ and a relative humidity of 35%, and stir for 7 minutes to obtain a water-soluble sleep-aiding compound factor solution. S4. Microencapsulation and multilayer wet integration: The process is the same as step S4 in Example 1; S5. Spray drying of the multilayer microencapsulated composite emulsion: The multilayer microencapsulated composite emulsion obtained in step S4 is fed into a nitrogen circulating spray drying tower, with the inlet temperature controlled at 175℃ and the outlet temperature at 82℃. The drying medium is nitrogen and the oxygen content of the outlet air is 2%v / v, to obtain multilayer microencapsulated composite powder with an encapsulation rate of 92%. S6. High-barrier nitrogen-filled packaging of multi-layer microencapsulated composite powder: Multi-layer microencapsulated composite powder is packaged using aluminum foil composite high-barrier packaging material, and nitrogen is replaced before heat sealing to control the headspace oxygen content in the packaging to 2%, thus obtaining a high-barrier nitrogen-filled packaged product.

[0061] Comparative Example 1: The difference from Example 3 is that mixed tocopherols and palmitic acid ascorbate are not added in step S1, while the rest are the same.

[0062] Comparative Example 2: The difference compared to Example 3 is as follows: Nitrogen gas is not introduced into the bubble in step S1; In step S5 (formerly S4), hot air (instead of nitrogen) is used for spray drying; Step S6 (original S7) does not involve nitrogen replacement; all other steps are the same.

[0063] Comparative Example 3: Compared with Example 3, the difference is that the microfluidic chip system in step S4 (original S3) is not used. Instead, the oil phase in step S1, the aqueous emulsion in step S2, and the water-soluble sleep-aiding compound factor solution in step S3 are emulsified together in a high-shear emulsifier at 10,000 rpm for 10 minutes to form an integrated mixed emulsion. This emulsion then enters step S5 for drying. The rest is the same.

[0064] Comparative Example 4: Compared to Example 3, the difference is that the microencapsulation, integration, and drying steps S1-S5 (original S1-S4) are not performed. All components of the formulation in Example 3 (phosphatidylserine powder, caprylic / capric triglyceride, sodium octenyl succinate starch, whey protein isolate, γ-aminobutyric acid, etc.) are physically mixed in dry powder form under normal conditions to obtain the final mixed powder, and then packaged in step S6.

[0065] Comparative Example 5: Compared to Example 3, the difference is that the separate step S3 is omitted. All the water-soluble sleep-aiding factors in step S3 are dissolved together with the wall material in the aqueous phase in step S2 to prepare an integrated composite aqueous phase.

[0066] In the subsequent step S4, only the oil phase from step S1 and the integrated composite aqueous phase are pumped into the microfluidic chip system for encapsulation to form an integrated microcapsule emulsion, and then proceed to step S5 for drying. The rest are the same.

[0067] Comparative Example 6: Compared with Example 3, the difference is that in step S2, sodium octenyl succinate starch, whey protein isolate and soybean lecithin are not used as composite wall materials, but are replaced with an equal amount (3.02 parts) of maltodextrin, while the rest are the same.

[0068] Test Example 1: Experimental steps: Sample preparation: Take the final finished powder (nitrogen-filled packaged finished product of step S6) prepared in Examples 1-5 and Comparative Examples 1-6, and take 3 independent packaged samples from each group as parallels.

[0069] Accelerated storage conditions: All samples (keeping their original packaging) were placed in a constant temperature and humidity chamber, and the accelerated degradation conditions were set as follows: temperature (45±1)℃, relative humidity (75±5)%RH.

[0070] Sampling and testing: Samples were taken out on days 0, 15, 30, and 60 of accelerated storage. Samples were taken immediately after unpacking, and the peroxide value (POV) of the oils in the samples was determined using GB5009.227-2016, "National Food Safety Standard - Determination of Peroxide Value in Food" (titration method). The average value of the three parallel samples was recorded.

[0071] The test results are shown in Table 1: Table 1: Changes in peroxide value (POV) of samples during accelerated storage at 45℃ From Table 1, we can obtain: The samples prepared in Examples 1-5 of this invention maintained an extremely low peroxide value (range 0.28-0.99 mmol / kg) below 1.0 mmol / kg after being stored at 45°C and high humidity for 60 days. This indicates that the multilayer microencapsulated complex powder prepared by the present invention has high oxidative stability.

[0072] First, a chemical antioxidant system is fundamental. Comparing Example 3 (60-day POV 0.62) with Comparative Example 1 (S1 without antioxidant, 60-day POV 16.4), the latter's POV value is more than 26 times that of the former. This confirms that the mixed tocopherols and palmitic acid ascorbate added in step S1 play a decisive role in inhibiting the chain oxidation reaction of PS during processing and storage.

[0073] Secondly, end-to-end low-oxygen process control is essential. The sample from Comparative Example 2 (S1 without deoxygenation, S5 hot air drying, S6 without nitrogen purging) had an initial POV (1.15) higher than that of Example 3 (0.31), and the POV value increased to 19.2 after 60 days of storage. This indicates that end-to-end low-oxygen environment control, from oil phase deoxygenation and spray drying media to the headspace of the finished product packaging, is a key process guarantee to prevent initial oxidation of PS during preparation and ensure long-term storage stability.

[0074] Finally, the dense physical structure formed by microfluidics provides additional protection. Comparative Example 3 (high shear integration), Comparative Example 5 (microfluidic integration), and Comparative Example 6 (maltodextrin wall material) all used the same antioxidants and low-oxygen process as Example 3, but their 60-day POV values ​​(5.6, 4.8, and 11.3, respectively) were still higher than those of Example 3 (0.62).

[0075] Test Example 2: Experimental steps: Take the powder from Examples 1-5 and Comparative Examples 1-6 after step S5 (spray drying) and before step S6 (packaging). Take 3 parallel samples from each group for testing.

[0076] Total oil determination ( ): Accurately weigh a certain amount ( The powder sample was subjected to acid hydrolysis-ether extraction (referring to GB5009.6-2016) to disrupt the microcapsule structure and extract the total oil from the powder. After drying and constant weight determination, the total oil mass was measured. ).

[0077] calculate: .

[0078] Surface oil measurement ( ): Accurately weigh a certain amount ( The powder sample was subjected to a room-temperature hexane rinsing method: the sample was placed in a filter paper tube and continuously rinsed with hexane (room temperature, non-boiling) in a Soxhlet extractor for 1 hour. This condition only dissolves the free PS oil on the powder surface without destroying the microcapsule structure. The hexane phase was collected, the solvent was removed by rotary evaporation, and the sample was dried and weighed after constant weight. ).

[0079] calculate: .

[0080] Encapsulation rate calculation: .

[0081] The test results are shown in Table 2: Table 2: Oxidative Stability (TBA Value) Accelerated Storage Test From Table 2, we can obtain: The samples prepared in Examples 1-5 (of the present invention) all achieved high encapsulation rates, with EE values ​​ranging from 85.3% to 99.1%. This indicates that the combination of the S2 composite wall material system and the S4 microfluidic integrated process used in this invention is feasible, effectively encapsulating the PS oil phase within the microcapsule core while maintaining a low level of free oil content on its surface.

[0082] By comparing various data points, the impact of different factors on the embedding rate can be analyzed: Antioxidant and low-oxygen processes (Comparative Examples 1 and 2): The encapsulation rates of Comparative Example 1 (without antioxidant) and Comparative Example 2 (without low-oxygen process) (95.1% and 94.9%, respectively) were basically consistent with those of Example 3 (95.6%). This result indicates that the addition of antioxidants in S1 and the low-oxygen control in S1 / S5 / S6 are key factors affecting the chemical stability of the product (as shown in Test Example 1), but they do not directly participate in the formation of the microcapsule physical structure and have no significant impact on the encapsulation rate.

[0083] Comparison of embedding processes (Comparative Examples 3 and 4): The embedding rate of Comparative Example 4 (physical mixing) was only 0.8%, indicating that the unprotected PS grease was completely exposed. The embedding rate of Comparative Example 3 (high shear integration) (66.7%) was much lower than that of Example 3 (95.6%). This demonstrates that the S4 microfluidic chip system, especially the compaction effect of its downstream swirling microstructures on the wall material, is the core technology for forming a high-density, high-embedding-rate structure. The droplets formed by conventional high-shear emulsification are uneven and loosely structured, leading to a large amount of grease leakage during the S5 drying process.

[0084] Wall material formulation comparison (Comparative Example 6): The encapsulation rate of Comparative Example 6 (S2 wall material replaced with maltodextrin) was only 48.4%, almost the lowest among all encapsulation groups. This indicates that the composite wall material system composed of sodium octenyl succinate starch, whey protein, and lecithin in the S2 formulation is crucial. This composite system provides excellent emulsifying ability and film-forming properties, while maltodextrin lacks these properties and cannot form an effective interfacial film to encapsulate the oil phase, leading to encapsulation failure.

[0085] Microfluidic structure comparison (Comparative Example 5): The encapsulation rate of Comparative Example 5 (microfluidic integrated encapsulation) was 90.3%, which is much higher than that of high-shear (C3) and maltodextrin wall materials (C6), indicating that microfluidic technology itself has advantages. However, this value is still lower than that of the multilayer wet integration process used in Example 3 (95.6%). The data shows that the layer-by-layer integration process in step S4, which first forms the PS core emulsion and then encapsulates the water-soluble sleep-aiding factor in the liquid phase, can form a more stable core layer with a clear interface than the one-step co-encapsulation of all materials (Comparative Example 5), thus achieving a higher encapsulation rate.

[0086] Test Example 3: Experimental steps: Simulated digestive fluid preparation: Simulated gastric juice (SGF): Prepare a solution with pH 2.0 (containing pepsin).

[0087] Simulated intestinal fluid (SIF): Prepare a solution with pH 6.8 (containing trypsin and bile salts).

[0088] In vitro simulated digestion: Equal amounts (based on PS content) of the finished powders from Examples 1-5 and Comparative Examples 1-6 were accurately weighed.

[0089] Stomach stage (0-60 min): Add the sample to SGF and shake in a constant temperature shaking incubator at 37℃ and 100 rpm. Remove the digest at 15, 30, and 60 minutes.

[0090] Intestinal phase (60-240 min): At 60 minutes, add SIF to the supernatant, adjust the pH to 6.8, and continue shaking at 37°C and 100 rpm. Collect the digestive fluid at 90, 120, 180, and 240 minutes.

[0091] Sample Analysis: All digestive fluid samples were subjected to enzyme inactivation and centrifugation, and the supernatant was collected. The concentrations of L-theanine (representing a water-soluble sleep-aiding factor) and phosphatidylserine were determined using high-performance liquid chromatography (HPLC). The cumulative release rate was calculated.

[0092] The test results are shown in Table 3.

[0093] Table 3: In vitro layered release test data (cumulative release rate %) From Table 3, we can obtain: During the SGF (stomach) stage, the cumulative release rate of L-theanine (outer layer water-soluble factor) exceeded 80% (81.6%-89.2%) within 30 minutes, achieving rapid release. Simultaneously, the release rate of PS (core layer) was effectively blocked by the S2 wall material, remaining at an extremely low level (5.8%-12.1%), thus being protected in the acidic gastric environment. Only after entering the SIF (intestine) stage did PS begin to be released continuously, reaching a high release rate (86.9%-91.5%) at 240 minutes. This result confirms that the multilayer wet integration process in step S4 of this invention successfully constructed a multilayer structure with water-soluble factors on the outside and PS oil phase in the core.

[0094] Compared with Example 3: Comparative Example 5 (Microfluidic Integration): This set of data (L-theanine SGF release rate of only 14.8%) forms the most crucial comparison with Example 3 (86.3%). C5 also employed microfluidic technology (high encapsulation rate, see Test Example 2), but because it premixed the water-soluble factor (S3) with the wall material (S2), L-theanine was encapsulated together in the core layer, preventing rapid release. This demonstrates that the multilayer wet integration in step S4 (encapsulating the core first, then the outer layer) is the structural basis for achieving layered release, rather than the microfluidic technology itself. Comparative Example 3 (High Shear Integration) also exhibited a similar problem (L-theanine release rate of 21.3%).

[0095] Comparative Example 4 (Physical Mixture): Data from this group showed that L-theanine (99.1%) and PS (97.8%) were completely released within 30 minutes of SGF. This indicates that unencapsulated PS is intolerant of gastric acid and completely lacks sustained-release properties.

[0096] Comparative Example 6 (Maltoidin Wall Material): The SGF data in this group (L-theanine 73.4%, PS 68.2%) indicate that the maltodextrin wall material is largely dissolved or broken down in the SGF, leading to the simultaneous (non-stratified) release of PS and L-theanine, a behavior close to C4 (physical mixing). This conversely demonstrates the necessity of the S2 composite wall material (sodium octenyl succinate starch, whey protein, etc.) for protecting the PS core and enabling its targeted release into the intestine.

[0097] Comparative Examples 1 and 2 (no antioxidant / low oxygen): their release curves are almost identical to those of Example 3, indicating that oxidation control mainly affects chemical stability (Test Example 1) without changing the physical release structure constructed by the S4 process.

[0098] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A layered, slow-release phosphatidylserine and sleep-aiding factor nutritional formula, characterized in that, The nutritional formula comprises the following components by weight: Phosphatidylserine: 0.5-1.7 parts; Caprylic / capric triglycerides: 1.5-8.5 parts; Sodium octenyl succinate starch: 0.8-3.5 parts; Whey protein isolate: 0.4-2.0 parts; Soy lecithin: 0.008-0.05 parts; Mixed tocopherols: 0.0005-0.005 parts; Palmitic acid ascorbate: 0.0002-0.003 parts; γ-Aminobutyric acid: 0.3-0.8 parts; L-Theanine: 0.5-1.0 parts; Glycine: 6.0-15.0 parts; Magnesium glycine: 2.0-5.5 parts.

2. The nutritional formula of layered sustained-release phosphatidylserine and sleep-aiding factors according to claim 1, characterized in that, The nutritional formula also includes at least one selected from microcrystalline cellulose and maltodextrin; The amount of microcrystalline cellulose added is 1.0-2.0 parts; The amount of maltodextrin added is 0.3-1.0 parts.

3. The nutritional formula of layered sustained-release phosphatidylserine and sleep-aiding factors according to claim 1, characterized in that, The magnesium content in the glycine magnesium is 0.3-0.8 parts.

4. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula is characterized by, The preparation of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula as described in any one of 1-3 includes the following steps: S1. Construct a phosphatidylserine oil phase containing an antioxidant system; S2. Preparation of aqueous emulsion for composite wall material; S3. Prepare a water-soluble sleep-aiding compound factor solution; S4. Microencapsulate and compact the phosphatidylserine oil phase and the composite wall material aqueous phase emulsion to form a PS microencapsulated emulsion. Then, inject the water-soluble sleep aid composite factor solution for encapsulation and compact and encapsulate it with the wall material again to obtain a multilayer microencapsulated composite emulsion. S5. Spray dry the multilayer microencapsulated composite emulsion to obtain multilayer microencapsulated composite powder. S6. The multilayer microencapsulated composite powder is packaged with high-barrier nitrogen filling.

5. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula according to claim 4, characterized in that, S1 includes the following steps: Phosphatidylserine was mixed with caprylic / capric triglycerides, and mixed tocopherols and palmitic ascorbate were added. The mixture was stirred and dissolved at a constant temperature of 40-55℃, and nitrogen gas was bubbled through for 5-10 minutes to remove dissolved oxygen, thus obtaining a phosphatidylserine oil phase with a peroxide value of 0.1-0.5 mmol / kg.

6. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula according to claim 4, characterized in that, S2 includes the following steps: Sodium octenyl succinate starch, whey protein isolate, and soybean lecithin are dissolved in water and pre-emulsified for 3-8 minutes at 8000-15000 rpm using a high-shear emulsifier. Subsequently, the mixture undergoes two-stage high-pressure homogenization or membrane emulsification to form an aqueous emulsion of composite wall material with a particle size distribution coefficient (SPAN) in the range of 0.8-1.

0.

7. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula according to claim 4, characterized in that, S3 includes the following steps: Gamma-aminobutyric acid, L-theanine, glycine, and magnesium glycine are mixed in a three-dimensional motion mixer for 5-10 minutes at an ambient temperature of 15-24℃ and a relative humidity of 20-39% to obtain a water-soluble sleep aid module. Microcrystalline cellulose may be added to improve flowability.

8. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula according to claim 4, characterized in that, S4 includes the following steps: The phosphatidylserine oil phase and the composite wall material aqueous emulsion are pumped into a microfluidic chip system, where the oil phase and aqueous phase form embedded droplets in the fluid focusing channel. The embedded droplets flow through the swirling microstructure downstream of the chip and generate swirling motion under the action of fluid tangential stress, which compacts the surface wall material and forms PS microcapsule emulsion. The water-soluble sleep-aiding complex factor solution is injected into the downstream channel of the microfluidic chip, so that it coats the surface of the PS microcapsule emulsion and flows through the subsequent swirling microstructure and wall material-coated channel to form a multilayer microencapsulated complex emulsion.

9. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula according to claim 4, characterized in that, S5 includes the following steps: The multilayer microencapsulated composite emulsion is fed into a nitrogen circulating spray drying tower, with the inlet temperature controlled at 160-185℃ and the outlet temperature at 75-85℃. The drying medium is nitrogen and the oxygen content of the outlet air is 1-5% v / v, to obtain a multilayer microencapsulated composite powder with an encapsulation rate of 85-99%.

10. The preparation process of the layered sustained-release phosphatidylserine and sleep-aiding factor nutritional formula according to claim 4, characterized in that, S6 includes the following steps: The multi-layer microencapsulated composite powder is packaged using aluminum foil composite high-barrier packaging material, and nitrogen is purged before heat sealing to control the headspace oxygen content in the packaging to 1-5%, thus obtaining a high-barrier nitrogen-filled packaging product.

Images